DOCS vs. PSN, BLND, TEM, VTY, RMG, SPT, GEN, WIX, YOU, and CNIC
Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Persimmon (PSN), British Land (BLND), Templeton Emerging Markets Investment Trust (TEM), Vistry Group (VTY), Royal Mail (RMG), Spirent Communications (SPT), Genuit Group (GEN), Wickes Group (WIX), YouGov (YOU), and CentralNic Group (CNIC). These companies are all part of the "computer software" industry.
Dr. Martens vs. Its Competitors
Dr. Martens (LON:DOCS) and Persimmon (LON:PSN) are both consumer cyclical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.
Persimmon has higher revenue and earnings than Dr. Martens. Persimmon is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.
22.0% of Dr. Martens shares are held by institutional investors. Comparatively, 60.8% of Persimmon shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Comparatively, 2.6% of Persimmon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Persimmon has a net margin of 8.84% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Persimmon's return on equity.
Dr. Martens pays an annual dividend of GBX 0.02 per share and has a dividend yield of 0.0%. Persimmon pays an annual dividend of GBX 0.60 per share and has a dividend yield of 0.1%. Dr. Martens pays out 368.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Persimmon pays out 75.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Persimmon is clearly the better dividend stock, given its higher yield and lower payout ratio.
Dr. Martens has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Persimmon has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.
Dr. Martens presently has a consensus target price of GBX 6,000, indicating a potential upside of 6,533.50%. Persimmon has a consensus target price of GBX 1,503, indicating a potential upside of 31.67%. Given Dr. Martens' higher possible upside, equities research analysts plainly believe Dr. Martens is more favorable than Persimmon.
In the previous week, Dr. Martens and Dr. Martens both had 3 articles in the media. Dr. Martens' average media sentiment score of 1.09 beat Persimmon's score of 0.03 indicating that Dr. Martens is being referred to more favorably in the media.
Summary
Persimmon beats Dr. Martens on 11 of the 17 factors compared between the two stocks.
Get Dr. Martens News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Martens Competitors List
Related Companies and Tools
This page (LON:DOCS) was last updated on 10/9/2025 by MarketBeat.com Staff
